Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.14, Iss.3, 2009-09, pp. : 471-479

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging drugs for polycythemia vera

By Tibes Raoul Mesa Ruben A

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 3, 2013-09 ,pp. : 393-404

Informa Healthcare

Access to resources Recommend Favorite

Emerging drugs for myelofibrosis

By Atallah Ehab

Expert Opinion on Emerging Drugs, Vol. 17, Iss. 4, 2012-12 ,pp. : 555-570

Informa Healthcare

Access to resources Recommend Favorite

Pharmacological management of essential thrombocythemia

By Birgegård Gunnar

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. : 1295-1306

Informa Healthcare

Access to resources Recommend Favorite

Antiobesity Therapy: Emerging Drugs and Targets

Current Medicinal Chemistry, Vol. 13, Iss. 12, 2006-05 ,pp. : 1429-1460

Bentham Science Publishers

Access to resources Recommend Favorite

Comparison of JAK2^V617F‐positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 269-275

John Wiley & Sons Inc

Access to resources Recommend Favorite